Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Completed · Phase 2
Conditions studied: Lymphoma, Non-Hodgkin, Multiple Myeloma
In brief
Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100). The purpose of this protocol is to determine if plerixafor given after chemotherapy and G-CSF mobilization regimen is safe, if it can increase the circulating levels of peripheral blood stem cells (PBSCs) by ≥ 2-fold before apheresis, and if transplantation with the apheresis product was successful, as measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).
Key facts
- Study ID
- NCT00322387
- Run by
- Genzyme, a Sanofi Company
- People needed
- 40
- Starts
- 2004-04-01
- Expected to finish
- 2006-07-01
- Last updated by the study team
- 2014-03-13
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope National Medical Center — Duarte, California, United States
- Indiana Blood and Marrow Transplantation — Beech Grove, Indiana, United States
- University of Rochester Medical Center — Rochester, New York, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.